IMR Press / EJGO / Volume 25 / Issue 6 / pii/2004267

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Original Research

Survival and fertility of patients with malignant ovarian germ cell tumours

Show Less
1 Institute of Oncology, Department of Medical Oncology, Ljubljana (Slovenia)
Eur. J. Gynaecol. Oncol. 2004, 25(6), 702–706;
Published: 10 December 2004
Abstract

Disease-free survival (DFS), overall survival (OS) and fertility of patients treated for malignant ovarian germ cell tumours at the Institute of Oncology Ljubljana from 1990-2000 were assessed. Twenty-three patients with a median age of 25 (15-67) years were treated. Five had pure dysgerminoma, three endodermal sinus tumour, ten immature teratoma and five had mixed germ cell tumours. Eleven patients had FIGO Stage I and the others advanced stage disease. All patients underwent initial surgery; in 13 of 15 patients under 35 years unilateral salpingo-oophorectomy was performed. Twenty-one patients received adjuvant cisplatin-based chemother­apy. At the median follow-up of 68 (11-140) months DFS was 74% and OS 87%. Six patients (two did not receive adjuvant chemotherapy) relapsed at a median of 16 (3-63) months after surgery. At relapse four were treated with surgery and chemotherapy, one with chemotherapy only and one with palliative radiotherapy only: two are still in complete remission, one has residual disease and three died of disease. Ten of 13 patients with fertility-preserving surgery regained menstrual cycles and one gave birth to a normal child. DFS and OS in our group of patients (over I 5 years of age) are comparable to other institution's experience. Fertil­ity in young patients can be preserved without compromising outcome.

Keywords
Malignant ovarian germ cell tumours
Fertility preserving surgery
Cisplatin-based chemotherapy
Menstrual function
Survival.
Share
Back to top